Airfinity forecasts fewer doses to be delivered this year than COVAX

Posted on Jul 21, 2021

Airfinity is forecasting a 24.3% shortfall in deliveries to COVAX this year than is forecasted by the scheme.

COVAX is forecasting 1.86b vaccine doses to be delivered by the end of December 2021. Based on analysis of doses secured to date, Airfinity is forecasting this to be 1.407b doses delivered.

Airfinity’s number is lower due to several factors that are considered, rather than taking company projections at face-value, which have often not been realised. COVAX are expecting deliveries from vaccines that are yet to be approved and in some cases efficacy data is not yet available, such as Clover and Sanofi/GSK.

Airfinity’s forecasts also use real-time production data and historic trends in scale-up challenges, resulting in a lower output than COVAX have forecast, notably in candidates such as Novavax, who have shown many difficulties in their fragmented production network.

For more information or if you have specific data requests, contact the team at

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022